Changes in body composition during therapy with SGLT2 inhibitors in patients with chronic kidney disease

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00028560

Enrollment

Registered

2022-03-18

Start date

2021-03-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

N18

Interventions

Group 1: Prospective observational study: Patients with CKD and initiation of therapy with an SGLT2 inhibitor for clinical indication for 6 months

body composition measured by bioimpedance spectroscopy, blood pressure, body weight and laboratory parameters are measured.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Chronic kidney disease, initiation SGLT2 inhibitor for clinical indication

Exclusion criteria

Exclusion criteria: No informed consent.

Design outcomes

Primary

Measure	Time frame
Change in volume status (measured by bioimpedance spectroscopy) at clinical control points during the observation period	—

Secondary

Measure	Time frame
Change of blood pressure, body weight, laboratory parameters at clinical control points during the observation period	—

Countries

Germany

Contacts

Public ContactAnja Schork

Medizinische Klinik IV, Universitätsklinikum Tübingen

anja.schork@med.uni-tuebingen.de+49 (0)7071/29-82712

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026